56053-55-5

Basic information

• Product Name: 2-cyano-2-(3-oxocyclohexa-1-en-1-yl)acetamide
• Synonyms: 2-cyano-2-(3-oxocyclohexa-1-en-1-yl)acetamide
• CAS NO: 56053-55-5
• Molecular Weight: 178.191
• Mol File: 56053-55-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-cyano-2-(3-oxocyclohexa-1-en-1-yl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-cyano-2-(3-oxocyclohexa-1-en-1-yl)acetamide(56053-55-5)
• EPA Substance Registry System: 2-cyano-2-(3-oxocyclohexa-1-en-1-yl)acetamide(56053-55-5)

Safety Data

• Hazardous Substances Data: 56053-55-5(Hazardous Substances Data)

Upstream product

• 5682-75-7 3-chloro-2-cyclohexenone 
• 107-91-5 cyanoacetic acid amide 

Downstream Products

• 51369-14-3 3,8-dioxo-2-phenyl-2,3,5,6,7,8-hexahydroisoquinoline-4-carbonitrile 

Relevant articles and documents

Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor

The receptor tyrosine kinase Axl plays important roles in promoting cancer progression, metastasis, and drug resistance and has been identified as a promising target for anticancer therapeutics. We used molecular modeling-assisted structural optimization starting with the low micromolar potency compound 9 to discover compound 13c, a highly potent and orally bioavailable Axl inhibitor. Selectivity profiling showed that 13c could inhibit the well-known oncogenic kinase Met with equal potency to its inhibition of Axl superfamily kinases. Compound 13c significantly inhibited cellular Axl and Met signaling, suppressed Axl- and Met-driven cell proliferation, and restrained Gas6/Axl-mediated cancer cell migration or invasion. Furthermore, 13c exhibited significant antitumor efficacy in Axl-driven and Met-driven tumor xenograft models, causing tumor stasis or regression at well-tolerated doses. All these favorable data make 13c a promising therapeutic candidate for cancer treatment.

QUINOLINE DERIVATIVE

This compound represented by general formula (I) and having a quinoline skeleton has a strong Axl inhibitory activity. Consequently, this compound can be a therapeutic agent for Axl-related diseases, for example, cancers such as acute myeloid leukemia, chronic myeloid leukemia, melanoma, breast cancer, pancreatic cancer and glioma, kidney diseases, immune system diseases and cardiovascular diseases.

11β-Alkyl-2-azaestratrienes and intermediates

11β-Alkyl-2-azaestratrienes, displaying valuable pharmacological properties, e.g. anti-viral and hypolipemic, are manufactured by a total synthesis originating with dihydroresorcinol.